Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

FDA Approval Tweaks Decades-Old Treatment of Hodgkin's Lymphoma

Published: Tue, 20 Mar 2018 16:51:04 EDT
The approval adds to the indications with which brentuximab can used in the treatment of classic Hodgkin's lymphoma.
FDA Approvals

New Test Identifies 'Late Awakeners' After Cardiac Arrest

Published: Tue, 20 Mar 2018 16:49:36 EDT
Use of diffusion tensor MRI predicted outcome with a high degree of accuracy in patients still comatose more than 7 days after arrest, which should save many lives as well as reduce suffering and costs.
Medscape Medical News

Back to Basics: Barium Effective in Diagnosing Achalasia

Published: Tue, 20 Mar 2018 15:35:30 EDT
Dr David Johnson on the continued high value of this readily available technology.
Medscape Gastroenterology

Suicide Rates Higher for Patients With Urologic Cancers

Published: Tue, 20 Mar 2018 15:26:07 EDT
Patients with urologic cancers are five times more likely to commit suicide than those in the general population, warn researchers who say uro-oncology services require more psychiatric intervention.
Medscape Medical News
Displaying results 1-4 (of 20)
 1 - 2 - 3 - 4 - 5 


Medicxi founds biotech creation engine C21Med

Published: Tue, 20 Mar 2018 13:45:22 +0000
Medicxi has created an “ideas factory” to boost its capacity to turn early-stage science into pipelines of drug candidates and startups to develop them. The VC fund is setting up the venture with its CSO, David Grainger, Ph.D., and Johnson & Johnson’s Richard Mason. 

Ocugen preps dry eye disease drug for phase 3

Published: Tue, 20 Mar 2018 13:42:51 +0000
Eye disease specialist Ocugen remains on course to have two drugs in late-stage testing before the end of the year as its dry eye disease candidate OCU310 clears a phase 2 trial.

Kerrisdale targets Proteostasis’ ‘ineffective’ cystic fibrosis drug in latest short attack

Published: Tue, 20 Mar 2018 12:06:49 +0000
Kerrisdale Capital has fixed on cystic fibrosis biotech Proteostasis Therapeutics in its latest attack. The short seller launched the assault after seeing shares in Proteostasis rise 200% in three months on the back of data from a small midphase trial and the receipt of an FDA breakthrough tag.

Anti-flu drug exploits weakness in H3N2 strain

Published: Mon, 19 Mar 2018 15:52:58 +0000
A research team led by the University of California at San Diego has developed a small molecule that they believe could weaken or even stop the virulent H3N2 strain of flu in its tracks. It works by exploiting a flaw in the mechanism the virus uses to replicate.
Displaying results 1-4 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy